Innovent Biologics, Inc.

1801

KYG4818G1010

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:24 2024-07-08 EDT			5-day change	1st Jan Change
37.8 ^HKD	-4.67%		+2.72%	-11.58%

07-05	Innovent Biologics, Inc. and IASO Biotechnology Enhance Strategic Collaboration in Cell Therapy	CI
07-05	Nanjing IASO Biotherapeutics announced that it expects to receive funding from Innovent Biologics, Inc.	CI

Nanjing IASO Biotherapeutics announced that it expects to receive funding from Innovent Biologics, Inc.

July 04, 2024

Nanjing IASO Biotherapeutics announced that it will receive investment in a equity round of funding from new investor Innovent Biologics, Inc. for 18% stake on July 5, 2024.

Latest news about Innovent Biologics, Inc.

Innovent Biologics, Inc. and IASO Biotechnology Enhance Strategic Collaboration in Cell Therapy	07-05	CI
Nanjing IASO Biotherapeutics announced that it expects to receive funding from Innovent Biologics, Inc.	07-04	CI
Novo Nordisk's Wegovy Weight-Loss Drug Gets Approval in China	06-25	DJ
Innovent Biologics, Inc. Presents the Results of the First Phase 3 Study of Mazdutide for Weight Management at the ADA's 84th Scientific Sessions	06-24	CI
Innovent Biologics, Inc Receives Fast Track Designation from the U.S. FDA for IBI343 (TOPO1i anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer	06-12	CI
Innovent Biologics, Inc. Presents at 2024 ASCO Annual Meeting on Clinical Data of Anti-CLDN18.2 ADC in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer	06-01	CI
Innovent Biologics, Inc. Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib (ROS1 Inhibitor) Publishes in JCO and Reports at 2024 ASCO Annual Meeting	06-01	CI
Innovent Biologics, Inc. Presents Phase 1 Clinical Data of First-In-Class PD-1/IL-2a Bispecific Antibody Fusion Protein in Melanoma, Colorectal Cancer and Other Solid Tumors at 2024 ASCO Annual Meeting	06-01	CI
Innovent Biologics, Inc. Announces Picankibart Achieved Primary Endpoints in A Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to the NDA to the NMPA	05-27	CI
Chinese Regulator Accepts Innovent Biologics' New Drug Application for Thyroid Eye Disease Drug	05-20	MT
Innovent Biologics Announces National Medical Products Administration of China Accepts the New Drug Application for IBI311	05-20	CI
Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer	05-06	CI
Innovent Biologics, Inc. Announces Board and Committee Changes	05-03	CI
Innovent Biologics, Inc. Reports Revenue Results for the First Quarter of 2024	04-30	CI
Innovent Biologics, Inc. Appoints Samuel Zhang as Global Chief Business Officer	04-30	CI
Innovent Appoints Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer	04-16	CI
Hutchmed endometrial cancer treatment application accepted for review	04-02	AN
Hutchmed, Innovent Biologics Say Chinese Regulator Accepts Application for Endometrial Cancer Drug Combination	04-02	MT
HSBC in special payout on Canada sale; Astra FDA win	04-02	AN
Innovent Biologics New Cancer Drug Gets NDA from Chinese Authority	04-02	MT
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status	04-02	CI
Innovent Biologics, Inc. Announces the National Medical Products Administration Accepts the New Drug Application	04-02	CI
Innovent Biologics' Loss Narrows in 2023 as Revenue Grows	03-20	MT
Innovent Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
Innovent Biologics, Inc. Releases the Results of Two Clinical Studies of Ibi311 (An Anti-IGF-1R Monoclonal Antibody) in Oral Presentations At the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024	03-06	CI

Chart Innovent Biologics, Inc.

Duration

Period

More charts

Innovent Biologics Inc is an investment holding company principally engaged in biopharmaceuticals. The Company and its subsidiaries are engaged in research and development of antibody and protein medicine products, sale and distribution of pharmaceutical products, and provision of consultation and research and development services. The Company's main product is Tyvyt (sintilimab injection), which is used to treat relapsed or refractory classical Hodgkinâs lymphoma. The Company's products also include adalimumab biosimilar IBI-303, which is used to treat rheumatoid arthritis, ankylosing spondylitis and psoriasis. Bevacizumab biosimilar IBI-305 is used to treat metastatic colorectal cancer and advanced, metastatic or recurrent non-small-cell lung cancer (NSCLC). Rituximab biosimilar IBI-301 is used to treat non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Its products are used in oncology, metabolic, immunology and ophthalmology diseases.

Sector

Pharmaceuticals

Calendar

2024-08-20 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Innovent Biologics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

35.18 CNY

Average target price

51.93 CNY

Spread / Average Target

+47.60%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
INNOVENT BIOLOGICS, INC.	-11.58%	8.26B
CSL LIMITED	+3.11%	97.7B
SAMSUNG BIOLOGICS CO.,LTD.	+4.21%	41.43B
BIOGEN INC.	-11.74%	32.85B
UCB	+80.99%	29.33B
BIOMARIN PHARMACEUTICAL INC.	-13.72%	15.47B
INCYTE CORPORATION	-7.17%	12.89B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-13.08%	11.51B
ALTEOGEN INC.	+176.65%	10.74B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-57.36%	8.97B

Biopharmaceuticals

Innovent Biologics, Inc.

Equities

1801

KYG4818G1010

Pharmaceuticals

Nanjing IASO Biotherapeutics announced that it expects to receive funding from Innovent Biologics, Inc.

Latest news about Innovent Biologics, Inc.

Chart Innovent Biologics, Inc.

Company Profile

Income Statement Evolution

Ratings for Innovent Biologics, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Biopharmaceuticals